Evidence map›Paper›PMID 24603397›Full record

ArticleDigestive diseases (Basel, Switzerland)2014

Management of refractory eosinophilic esophagitis.

Vincent A Mukkada, Glenn T Furuta

Abstract readCase Reports
In one paragraph

Article in Digestive diseases (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Systematic review of histological remission criteria in eosinophilic esophagitis.JGH open : an open access journal of gastroenterology and hepatology · 2018
    Review
  4. Review
  5. Management of refractory eosinophilic oesophagitis.Nature reviews. Gastroenterology & hepatology · 2017
    Review
  6. Eosinophilic esophagitis: From pathophysiology to treatment.World journal of gastrointestinal pathophysiology · 2015
    Review
  7. Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vincent A MukkadaDivision of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Glenn T Furuta

Funding

Patient research in eosinophilic gastrointestinal diseasesK24DK100303 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI FURUTA, GLENN T · 2013 to 2017
$889k
NIDDK NIH HHS 1K24DK100303NIDDK NIH HHS K24 DK100303
6 · The paper itself

Abstract

BACKGROUND/

aimsWhereas most children and adults respond to traditional eosinophilic esophagitis (EoE) treatments, such as exclusion of dietary allergens or the use of topical steroids, a small fraction may not.

methodsBased on clinical experience and a review of the literature, the aim of this work is to provide practical advice for caring for 'refractory' patients with EoE.

resultsThe approach to this type of patient continues to evolve and decision-making should consider a number of issues including the patient's age, lack of a complete understanding of the natural history of this disease, risks of monitoring, and side effects of treatments. Next, one needs to define the term 'refractory' in that this can refer either to persistent symptoms or to continued inflammation in the face of presumably effective drug or diet therapy. Before considering alternative treatments, it is important to rule out any other cause of persistent symptoms. For instance, could they be related to an occult esophageal narrowing not identified at the time of endoscopy? Esophagrams may be necessary to identify localized or longitudinal narrowing that could be amenable to dilation. If symptoms and inflammation persist and no narrowing is appreciated, an elemental diet can be considered; however, the long-term use of this in older children and adults may be difficult. Prednisone or systemic steroids may be indicated to induce remission, but side effects and complications associated with chronic use are limiting. Finally, the use of immunosuppression or biological agents has been reported in case reports and studies; use of these may be limited by side effects or the need to utilize compassionate use protocols.

conclusionsAs the scope of esophageal eosinophilia continues to evolve, the clinical and molecular characterization of new clinical phenotypes will be important so that new therapeutic targets can be identified.

Indexed as

ChildChild, PreschoolEosinophilic EsophagitisFamilyHumansMalePolypharmacy

Identifiers

PMID24603397
PMCPMC4081443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.